GlassScriptPhysician profile
Carrie E Montgomery
NPI 1871256628
$1,868.09
in general payments reported to CMS, 2019-2025
18 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $892 · 2024: $492 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.62 | 2022-2025 | |
| Glaxosmithkline, LLC. | $191.28 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $122.79 | 2024 | Voquezna |
| Lilly USA, LLC | $120.33 | 2023-2024 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $119.37 | 2023-2025 | |
| Organon LLC | $110.70 | 2023-2024 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $97.14 | 2024-2025 | Farxiga, Airsupra |
| Medtronic, INC. | $87.82 | 2023 | Interstim |
| Exact Sciences Corporation | $72.18 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.06 | 2025 | Caplyta |
| Novo Nordisk INC | $61.19 | 2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $49.70 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $47.92 | 2024 | Veozah |
| Radius Health, INC. | $21.93 | 2023 | Tymlos |
| Merck Sharp & Dohme LLC | $21.16 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.00 | 2023 | Trintellix |
| Lundbeck LLC | $15.41 | 2023 | Rexulti |
| Janssen Biotech, INC. | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.